Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population

Komosińska-Vassev, Katarzyna; Blat, Dorota; Olczyk, Paweł; Szeremeta, Anna; Jura-Półtorak, Agnieszka; Winsz-Szczotka, Katarzyna; Klimek, Katarzyna; Olczyk, Krystyna

doi:10.1016/j.clinbiochem.2014.06.012

Cited by 18 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Other outcome measures also may be affected by patient demographics. GAG excretion is known to be affected by age 18 and in this study was shown to be affected by sex. FVC may be influenced by age, sex (as shown in this study), as well as ethnicity.…”

Section: Discussionsupporting

confidence: 49%

Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I

Laraway¹,

Mercer²,

Jameson³

et al. 2016

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 49%

Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I

Laraway¹,

Mercer²,

Jameson³

et al. 2016

The Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

“…Differently from us, in adult patients with rheumatoid diseases was demonstrated increased urinary HA excretion [35,36]. Considering the strong effect of age on GAGs excretion in the urine [37], it is difficult to compare our findings with the results of the cited above work. The observed urinary HA levels in JIA patients, which might result from enhanced degradation of this type of GAG, taking place with hyaluronidases action in the liver or kidneys and the spleen.…”

Section: Discussionmentioning

confidence: 63%

Plasma and urinary glycosaminoglycans in the course of juvenile idiopathic arthritis

Winsz-Szczotka

Kuźnik-Trocha

Komosińska-Vassev

et al. 2015

Biochemical and Biophysical Research Communications

Self Cite

View full text Add to dashboard Cite

“…Chondroitin sulfate is the most abundant GAG detected in urine in normal population, followed by hyaluronic acid, heparan sulfate, dermatan sulfate and keratan sulfate, respectively [19]. Many researchers reported low sulfated GAG excretion in urolithiasis patients [20, 21].…”

Section: Resultsmentioning

confidence: 99%

Urinary sulfated glycosaminoglycan insufficiency and chondroitin sulfate supplement in urolithiasis

et al. 2019

View full text Add to dashboard Cite

Familial members of urolithiasis have high risk for stone development. We observed the low sulfated glycosaminoglycan (GAG) excretion in urolithiasis patients and their descendants. In this study, we investigated urinary excretion of sulfated GAG, chondroitin sulfate (CS), heparan sulfate (HS) and hyaluronic acid (HA) in urolithiasis and their children, and explored the effect of CS and HA supplement in urolithic hyperoxaluric rats. The 24-hour urines were collected from urolithiasis patients (28) and their children (40), as well as healthy controls (45) and their children (33) to measure urinary sulfated GAG, CS, HS and HA excretion rate. Our result showed that urinary sulfated GAG and CS were diminished in both urolithiasis patients and their children, while decreased HS and increased HA were observed only in urolithiasis patients. Percentage of HS per sulfated GAG increased in both urolithiasis patients and their children. In hyperoxaluric rats induced by ethylene glycol and vitamin D, we found that CS supplement could prevent stone formation, while HA supplement had no effect on stone formation. Our study revealed that decreased urinary GAG and CS excretion are common in familial members of urolithiasis patients, and CS supplement might be beneficial in calcium oxalate urolithiasis prophylaxis for hyperoxaluric patients.

show abstract

Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population

Cited by 18 publications

References 11 publications

Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I

Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I

Plasma and urinary glycosaminoglycans in the course of juvenile idiopathic arthritis

Urinary sulfated glycosaminoglycan insufficiency and chondroitin sulfate supplement in urolithiasis

Contact Info

Product

Resources

About